<DOC>
	<DOCNO>NCT01153685</DOCNO>
	<brief_summary>This study design test safety immunogenicity Fluviral® ( 2010 - 2011 Season ) adult age 18 60 year 60 year .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study Fluviral® ( 2010 - 2011 Season ) Adults Aged 18 60 Years Over 60 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject Male female adult , 18 60 year age 60 year age . Satisfactory baseline medical assessment history physical examination Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Participation previous year 's ( 2009 ) Fluviral registration study Administration influenza vaccine within 6 month precede study start ( 35 subject &gt; 60 year old age stratum recruit among NOT receive inactivate influenza vaccine 20092010 season , i.e . seasonal TIV pandemic H1N1v ) . Administration vaccine ( ) within 30 day prior study enrollment study period . Subjects receive treatment enrollment follow per protocol include safety analysis , exclude accordingtoprotocol cohort . Clinically virologically confirm influenza infection within 1 year precede study start . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . Acute disease time enrollment . ( Acute disease define presence moderate severe illness without fever ) . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e . oral temperature &lt; 38.0°C . Significant acute chronic , uncontrolled medical psychiatric illness . `` Uncontrolled '' define : Requiring institution new medical surgical treatment within one ( 1 ) month prior study enrollment , Requiring reinstitution previously discontinue medication medical treatment within one month prior study enrollment , Requiring change medication dosage one month prior study enrollment due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) , Hospitalization event fulfil definition SAE within one month prior study enrollment . Any confirm suspected immunosuppressive condition include : History human immunodeficiency virus ( HIV ) infection , Cancer treatment cancer , within 3 year study enrollment . Persons history cancer diseasefree without treatment 3 year eligible . History renal impairment . History hepatic dysfunction due hepatitis B , C toxins include alcohol . Complicated insulindependent diabetes mellitus . Unstable cardiopulmonary disease require chronic medical therapy associate functional impairment . Presence blood dyscrasia , include hemoglobinopathy myelo lymphoproliferative disorder . Receipt systemic glucocorticoid ( prednisone &gt; = 20 mg/day 14 consecutive day ) within 1 month study enrollment , cytotoxic immunosuppressive drug within six month study enrollment . Inhaled topical steroid allow . A history demyelinate disease include Multiple Sclerosis GuillainBarré syndrome . Presence active neurological disorder . History chronic alcohol consumption and/or drug abuse . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g . lowdose aspirin , without clinicallyapparent bleeding tendency eligible . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan study . Any known suspected allergy constituent Fluviral ( egg protein , thimerosal ) and/or history anaphylactic type reaction consumption egg , and/or reaction product contain mercury ( thimerosal ) . A history severe adverse reaction previous influenza vaccination . Pregnant and/or lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Fluviral®Influenza</keyword>
</DOC>